Introduction
============

Cancer immunotherapy has gained interest due to the clinical efficacy of immune checkpoint inhibitors, including antibodies targeting programmed death-1 (PD-1), programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), in a number of cancer types, including melanoma, colorectal cancer (CRC), renal cell carcinoma and non-small cell lung carcinoma ([@b1-ol-0-0-9826]--[@b4-ol-0-0-9826]). Identification of factors that could predict the curative effect of anti-PD-1/L1 therapy is a major challenge. Mismatch repair protein (MMR) status has been reported to be a primary indicator for anti-PD-1/L1 therapy in patients with CRC, as only MMR-deficient (dMMR) patients are promising candidates ([@b2-ol-0-0-9826]). However, to the best of our knowledge, it is unknown why only dMMR patients are sensitive to anti-PD-1/L1 therapy. In addition, only certain dMMR patients benefit from the treatment ([@b2-ol-0-0-9826]), which suggests that other predictive factors should also be explored.

The tumor microenvironment is a complicated system that has the dual function of promoting and inhibiting tumor growth, which therefore influences drug response. The tumor microenvironment is composed of non-tumor cells, cytokines, chemokines and the extracellular matrix. Immune cells, particularly acquired immune cells, including T and B lymphocytes, are important non-tumor cells ([@b5-ol-0-0-9826]). The current study primarily focused on tumor infiltrating lymphocytes (TILs), crucial acquired immune cells, and PD-L1 expressed by tumor cells, which negatively affects the function of TILs. In human melanoma, the classification of tumor microenvironments based on TIL presence and PD-L1 expression has been proposed to predict and guide immunotherapeutic approaches ([@b6-ol-0-0-9826]). Among the four types of tumor microenvironments (TIL^+^ PD-L1^+^, TIL^+^ PD-L1^−^, TIL^−^ PD-L1^+^ and TIL^−^ PD-L1^−^), TIL^+^ PD-L1^+^ tumors exhibit the best response to checkpoint blockade and are the most inclined to benefit from single anti-PD-1/L1 agent therapy, as pre-existing intratumor T cells in these tumors are turned off by PD-L1 and reactivated by the agent ([@b7-ol-0-0-9826]). TIL^−^ PD-L1^+^ and TIL^−^ PD-L1^−^ tumors appear insensitive to single checkpoint blockade therapy due to a lack of pre-existing lymphocyte infiltrates, instead combination therapy is required to attract T cells into tumors ([@b8-ol-0-0-9826]--[@b10-ol-0-0-9826]).

TIL^+^ PD-L1^−^ tumors contain TILs, but no PD-L1 expression; therefore, without evident adaptive resistance, TIL^+^ PD-L1^−^ tumors may not be suitable for anti-PD-1/L1 therapy ([@b11-ol-0-0-9826]).

To the best of our knowledge, the typical TIL/PD-L1 status of patients with CRC has not previously been investigated. The current study enrolled 243 patients with CRC who were defined as pMMR or dMMR. The associations between MMR status, TIL expression and PD-L1 expression were investigated. In addition, the associations between TIL/PD-L1 status and clinicopathological features, particularly MMR status, were investigated to evaluate whether TIL/PD-L1 status could provide an explanation for the improved response of dMMR patients to anti-PD-1/L1 therapy and determine whether this classification method is suitable for efficacy prediction.

Patients and methods
====================

### Patients and specimens

Pathological specimens of CRC tissue were collected from 243 patients with CRC (121 pMMR patients and 122 dMMR patients) of stage I to IV who underwent primary surgery between March 2009 and December 2016 at Sun Yat-Sen University Cancer Center (Guangzhou, China). The obtained specimens were fixed in 10% formalin for 24 h at room temperature and embedded in paraffin for further use. Written informed consent was obtained from every patient. The study was performed according to the principles of the Declaration of Helsinki and was approved by the Research Ethics Committee of Sun Yat-Sen University (Gaungzhou, China).

### Estimation of TILs

T-lymphocyte density within the cancer cell nests and at the invasive margin, which denoted the interface between the invading edge area of the tumor and the host stroma, was identified and estimated using a hematoxylin and eosin (H&E) staining method. Briefly, tumor samples were paraffin-embedded and sliced into 4-µm sections. Slides were deparaffinized in xylene for 10 min three times and rehydrated in a descending alcohol series (100, 95, 85 and 75%) for 5 min each at 25°C. Subsequently, the samples were stained with H&E (cat no. 468802128; POCH S.A., Gliwice, Poland) at room temperature for 20 min. The sections were then observed with a light microscope (magnification, ×200). The intensity of the lymphocyte infiltrate was scored as follows: Score 0, none; score 1, weak, rare lymphocytes; score 2, moderate, focal infiltration; and score 3, severe, diffuse infiltration ([@b12-ol-0-0-9826]). Populations with scores of 0 and 1 were defined as TIL^−^, and those with scores of 2 and 3 were defined as TIL^+^.

### Immunohistochemistry and scoring

The immunohistochemistry experiment was conducted as previously described ([@b13-ol-0-0-9826]). To detect MMR proteins, mouse monoclonal antibodies against MutL homolog 1 (MLH1) (cat. no. ES05; 1:500), MutS homolog 2 (MSH2) (cat. no. FE11; 1:500), MutS homolog 6 (MSH6; cat. no. EP49; 1:500) and PMS1 homolog 2 (PMS2; cat. no. EP51; 1:500) (all from Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) were used. Rabbit monoclonal antibodies against PD-L1 (cat. no. 13684; 1:200; Cell Signaling Technology, Inc., Danvers, MA, USA) and PD-1 (cat. no. ab137132; 1:500; Abcam, Cambridge, UK) were also used to evaluate the expression of PD-L1 and PD-1. Samples embedded in paraffin were cut into 4-µm sections, deparaffinized in xylene, rehydrated through graded ethanol and dipped in 0.3% hydrogen peroxide for \>15 min to inactivate the endogenous peroxidase. The slides were then processed for antigen retrieval with high pressure cooking at 120°C for \~10 min in citrate antigen retrieval solution, followed by incubation with primary antibody at 4°C overnight. Following three washes with PBS, the slides were subsequently co-incubated with goat anti-rabbit or anti-mouse biotin-linked secondary antibodies for 30 min at 37°C (cat. no. SP-9000; 1:2,000; OriGene Technologies, Inc., Rockville MD, USA), counterstained with hematoxylin for 15 min at room temperature for color reaction and ultimately fixed in mounting media. The sections were observed with a light microscope (magnification, ×200). Staining without primary antibody served as a negative control. Each slide was examined by three pathologists.

Tumors expressing all four proteins, MLH1, MSH2, PMS2 and MSH6, were defined as pMMR and all other tumors were considered to be dMMR. The expression of PD-L1 in tumor cells was divided into two groups: \<5% positive cells was considered as negative and ≥5% was considered as positive ([@b3-ol-0-0-9826],[@b14-ol-0-0-9826]). PD-1 expression in TILs was scored as follows: Score 0, none (0% of lymphocytes); score 1, isolated (\<5% of lymphocytes); score 2, moderate (5--50% of lymphocytes; and 3, severe (\>50% of lymphocytes. Scores of 0 and 1 were considered as low expression and score of 2 and3 were considered as high expression ([@b7-ol-0-0-9826],[@b15-ol-0-0-9826]).

### Statistical analysis of the data

All statistical analyses were performed using SPSS 22.0 software (IBM Corp., Armonk, NY, USA). Pearson\'s χ^2^ test was used to assess the association between categorical variables. Multivariable multinomial logistic regression analysis was used for multivariate analysis to predict the odds ratio (OR) of individual factors for TIL^+^ PD-L1^+^ status. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

The clinicopathological characteristics of all 243 patients are presented in [Table I](#tI-ol-0-0-9826){ref-type="table"}. Patients were selected according to pMMR (121 patients) and dMMR (122 patients) status, including 189 patients with colon cancer (left, 90 patients; right, 99 patients) and 54 patients with rectum cancer. [Table II](#tII-ol-0-0-9826){ref-type="table"} presents the frequency of aberrant MMR protein expression in dMMR patients. The median age at the time of diagnosis was 60 years (range, 22--84 years), and 58.4% of patients were male and 41.6% were female. According to the American Joint Committee on Cancer (AJCC) 7th edition TNM staging system, pathologically confirmed stage I--IV disease was identified in 48 (19.8%), 135 (55.6%), 46 (18.9%) and 14 (5.8%) patients respectively. Moderately differentiated adenocarcinoma accounted for 58.4% of cases and well-differentiated adenocarcinoma accounted for 0.8% of all cases. A total of 20 (8.2%) and 28 (11.5%) patients exhibited vascular and nerve invasion, respectively.

### Association between MMR status, TILs, PD-L1 expression and other clinicopathological features

Representative images obtained to determine TIL presence and PD-L1 expression are presented in [Fig. 1](#f1-ol-0-0-9826){ref-type="fig"}. The presence of TILs was classified as positive or negative according to H&E staining. The degree of PD-L1 expression was based on IHC (negative, \<5% positive tumor cells; positive, ≥5% positive tumor cells). The associations of MMR status with TIL presence and PD-L1 expression are presented in [Table I](#tI-ol-0-0-9826){ref-type="table"}. The dMMR group exhibited a significantly higher frequency of TIL^+^ (85/122 vs. 61/121) and PD-L1^+^ expression (49/122 vs. 32/121) compared with the pMMR group (P\<0.05). Other clinicopathological characteristics, including age, primary tumor site, tumor stage, histological grade, C-reactive protein (CRP) level, vascular invasion and nerve invasion were also significantly associated with MMR status (P\<0.05).

### Association of TILs with PD-L1 expressed by CRC cells

The association between TIL frequency and PD-L1 expression by CRC cells was investigated in the pMMR and dMMR groups. As presented in [Table III](#tIII-ol-0-0-9826){ref-type="table"}, PD-L1^+^ expression was identified in 42.4% of TIL^+^ cases in the dMMR group, while PD-L1^+^ expression was only identified in 18.0% of TIL^+^ cases in the pMMR group. A significant association was revealed between the presence of TILs and PD-L1 expression in the pMMR group (P\<0.05), but not in the dMMR group (P\>0.05).

### Association between TIL/PD-L1 status and clinicopathological features

A total of 4 distinct groups were determined according to the presence of TILs and PD-L1: The presence of TILs and PD-L1 (TIL^+^ PD-L1^+^), the presence of TILs without PD-L1 (TIL^+^ PD-L1^−^), PD-L1 expression without TILs (TIL^−^ PD-L1^+^) and the absence of TILs and PD-L1 expression (TIL^−^ PD-L1^−^). The current study investigated whether TIL/PD-L1 status was associated with other clinicopathological features, particularly MMR status. As presented in [Table IV](#tIV-ol-0-0-9826){ref-type="table"}, TIL/PD-L1 status was significantly associated with AJCC stage, tumor stage, node stage, tumor histological grade, nerve invasion, neutrophil lymphocyte ratio, CRP level, PD-1 expression and MMR status (P\<0.05). These significantly associated features were then further analyzed by multivariable multinomial logistic regression analysis ([Table V](#tV-ol-0-0-9826){ref-type="table"}). The results demonstrated that PD-1 expression and MMR status were significantly associated with TIL/PD-L1 status. Taking TIL^+^ PD-L1^+^ as a reference, low PD-1 expression compared with high expression was associated with a higher likelihood of presenting as TIL^−^ PD-L1^−^ \[OR, 10.473; 95% confidence interval (CI), 3.005--36.503; P\<0.001\] and TIL^+^ PD-L1^−^ (OR, 3.443; 95% CI, 1.145--10.352; P=0.028). pMMR status compared with dMMR status was associated with an increased likelihood of being TIL^−^ PD-L1^−^ (OR, 11.536; 95% CI, 3.223--41.290; P\<0.001), TIL^−^ PD-L1^+^ (OR, 14.523; 95% CI, 3.358--62.803; P\<0.001) and TIL^+^ PD-L1^−^ (OR 4.718; 95% CI, 1.607--13.848; P=0.005). Compared with the pMMR group, the dMMR group was more likely to present with a TIL^+^ PD-L1^+^ status (76.6 vs. 23.4%; [Table IV](#tIV-ol-0-0-9826){ref-type="table"}).

Discussion
==========

Classification of tumor microenvironments according to the presence of TILs and PD-L1 expression has been established in certain cancer types, particularly human melanoma, and applied to predict the effect of anti-PD-1/L1 and select the optimum immunotherapy strategies ([@b6-ol-0-0-9826],[@b11-ol-0-0-9826]). However, to the best of our knowledge, the occurrence of the four types of immune microenvironments in CRC and their association with MMR status remains to be investigated. The current study performed this investigation and revealed a difference in TIL/PD-L1 status between pMMR and dMMR groups, with dMMR patients more likely to exhibit a TIL^+^ PD-L1^+^ tumor microenvironment.

Compared with the pMMR group, the dMMR group more frequently exhibited a TIL^+^ PD-L1^+^ phenotype. Previous studies have also demonstrated that tumors from dMMR patients contain a greater TIL density and higher PD-L1 expression compared with tumors from pMMR patients ([@b16-ol-0-0-9826]--[@b19-ol-0-0-9826]). The extent of DNA mutation directly or indirectly correlates with the strength of immunogenicity in tumors ([@b20-ol-0-0-9826]); therefore, the higher density of TILs in dMMR tumors may be due to the accumulation of frameshift mutations and the production of neo-antigens, which activates the immune system of the host ([@b21-ol-0-0-9826],[@b22-ol-0-0-9826]).

TILs upregulate PD-L1 expression through the release of interferon-γ, which mediates an adaptive immune-resistance mechanism by inhibiting local effector T cell activity ([@b6-ol-0-0-9826],[@b23-ol-0-0-9826]--[@b25-ol-0-0-9826]). This suggests that PD-L1 expression is an adaptive approach for tumor escape from cytokine-mediated T-cell killing. In accordance with previous studies, the current study revealed that PD-L1^+^ expression was significantly higher in the TIL^+^ dMMR group compared with that in the TIL^+^ pMMR group, which indicated that TILs may induce the expression of PD-L1 in the dMMR group. In addition, a negative association was identified between TILs and PD-L1 expression in the pMMR group, implying a complexity in the immune tolerance mechanism in this group that cannot be explained by the current study.

Previous studies have divided the tumor immune microenvironments into 4 groups namely TIL^+^PD-L1^+^, TIL^+^ PD-L1^−^, TIL^−^ PD-L1^+^ and TIL^−^ PD-L1^−^, according to PD-L1 expression and the presence or absence of TILs. The association of TILs with PD-L1 expression is considered to be more valuable for predicting the response to anti-PD-1/L1 therapy compared with TILs or PD-L1 expression alone ([@b26-ol-0-0-9826]). In TIL^+^ PD-L1^+^ tumors, a sufficient number of T cells exist inside the tumor that can induce adaptive expression of PD-L1, which in turn suppresses the function of T cells and may support an effective response to PD-1/L1 blockade therapy ([@b6-ol-0-0-9826],[@b7-ol-0-0-9826]). TIL^+^ PD-L1^−^ tumors account for \~20% of melanoma cases and contain TILs, but no PD-L1 expression, which indicates a lack of adaptive resistance and suggests that PD-1/L1 blockade is ineffective in this tumor type ([@b11-ol-0-0-9826]). No definite immunotherapy approaches have been applied in the clinic for patients with these tumors; therefore, novel immunosuppressive strategies should be developed in the future ([@b11-ol-0-0-9826]). In TIL^−^ PD-L1^+^ tumors, PD-L1 is expressed by tumor cells through oncogenic signaling instead of in response to TILs. It is unlikely that blocking PD-1 or PD-L1 alone is effective in this group due to a lack of T cell involvement ([@b11-ol-0-0-9826]). Radiotherapy or chemotherapy that induces cell death and the release of neo-antigens to induce a T-cell-mediated antitumor response has been used in combination with anti-PD-1 agents ([@b8-ol-0-0-9826],[@b27-ol-0-0-9826],[@b28-ol-0-0-9826]). Similar to that in TIL^−^ PD-L1^+^ tumors, single checkpoint blockade agents appear to be ineffective in TIL^−^ PD-L1^−^ tumors due to the lack of T-cell infiltrates. Combination therapy strategies that aim to attract T cells into tumors and prevent inhibition of T cells should be considered. CTLA-4, an inducer of numerous T-cell responses, in combination with anti-PD-1, has been confirmed to effective in a clinical trial, regardless of PD-L1 expression ([@b9-ol-0-0-9826],[@b10-ol-0-0-9826]). Based on the recognition that TIL^+^ PD-L1^+^ tumors exhibit the best response to PD-1/L1 blockade therapy, the current study assumed that dMMR patients contain a higher proportion of TIL^+^ PD-L1^+^ tumors compared with pMMR patients. The results confirmed this hypothesis and demonstrated that dMMR status is an independent risk factor for TIL^+^ PD-L1^+^ status. This could provide immunological evidence for an improved response to anti-PD-1/L1 therapy in dMMR patients compared with that in pMMR patients.

Immune checkpoint blockade is predominantly applied for patients with stage IV CRC ([@b2-ol-0-0-9826],[@b3-ol-0-0-9826]), therefore, the current study attempted to investigate dMMR patients with an advanced stage of CRC. However, dMMR patients account for only a small percentage of patients with stage IV disease and obtaining pathological specimens from these patients was limited due to the loss of surgical opportunities. Although some immunological evidence could be provided, the current study would be more valuable if a higher number of stage IV patients were included. The current study aimed to collect samples from multiple centers to solve this problem, however, this was difficult due to objective factors. This is a notable limitation of the present study, therefore, further investigations are required in the future.

In conclusion, the current study indicated that dMMR patients are more likely to express TILs and PD-L1, and present with a TIL^+^ PD-L1^+^ status compared with pMMR patients. Therefore, the tumor type identified by this classification method can partially explain the improved response of dMMR patients to PD-1/L1 blockade. However, the response of each tumor type to PD-1/L1 blockade requires further investigation.
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![Representative expression of TILs, PD-L1 and PD-1. (A) Absence and (B) presence of TILs at the central area of the tumor and the invasive margin. The presence of TILs was determined by hematoxylin and eosin staining. (C) Negative and (D) positive PD-L1 expression in tumor cells. (E) Low and (F) high expression of PD-1 by TILs. PD-L1 and PD-1 expression was determined by immunohistochemistry. Magnification, ×200. TIL, tumor-infiltrating lymphocyte; PD-L1, programmed death ligand-1; PD-1, programmed death-1.](ol-17-02-2335-g00){#f1-ol-0-0-9826}

###### 

Association analysis between MMR status and clinicopathological features using a χ^2^ test.

  Characteristic                                       pMMR, n (%)   dMMR, n (%)   C       P-value
  ---------------------------------------------------- ------------- ------------- ------- ---------
  Age at diagnosis, years                                                          0.190   0.003
    \<60                                               54 (44.6)     78 (63.9)             
    ≥60                                                67 (55.4)     44 (36.1)             
  Sex                                                                                      0.22
    Male                                               66 (54.5)     76 (62.3)             
    Female                                             55 (45.5)     46 (37.7)             
  Primary tumor site                                                               0.18    0.017
    Left colon                                         55 (45.5)     35 (28.7)             
    Right colon                                        40 (33.1)     59 (48.4)             
    Rectum                                             26 (21.5)     28 (23.0)             
  Stage^[a](#tfn1-ol-0-0-9826){ref-type="table-fn"}^                                       0.514
    I                                                  22 (18.2)     26 (21.3)             
    II                                                 73 (60.3)     62 (50.8)             
    III                                                20 (16.5)     26 (21.3)             
    IV                                                 6 (5.0)       8 (6.6)               
  Tumor stage                                                                      0.204   0.033
    T1                                                 6 (5.0)       5 (3.1)               
    T2                                                 21 (17.4)     24 (14.7)             
    T3                                                 82 (67.8)     63 (51.6)             
    T4a                                                9 (7.4)       22 (18.0)             
    T4b                                                3 (2.5)       8 (6.6)               
  Node stage                                                                               0.458
    Negative                                           97 (80.2)     93 (76.2)             
    Positive                                           24 (19.8)     29 (23.8)             
  Tumor histological grade                                                         0.186   0.033
    Well-differentiated                                1 (0.8)       1 (0.8)               
    Moderately differentiated                          80 (66.1)     62 (50.8)             
    Poorly differentiated                              19 (15.7)     18 (14.8)             
    Mucinous                                           21 (17.4)     41 (33.6)             
  Vascular invasion                                                                0.149   0.019
    No                                                 106 (87.6)    117 (95.9)            
    Yes                                                15 (12.4)     5 (4.1)               
  Nerve invasion                                                                   0.179   0.005
    No                                                 100 (82.6)    115 (94.3)            
    Yes                                                21 (17.4)     7 (5.7)               
  NLR^[b](#tfn2-ol-0-0-9826){ref-type="table-fn"}^                                         0.699
    Low (≤5)                                           109 (91.6)    110 (90.2)            
    High (\>5)                                         10 (8.4)      12 (9.8)              
  CRP, mg/l                                                                        0.201   0.001
    Low (≤5)                                           85 (72.0)     63 (52.1)             
    High (\>5)                                         33 (28.0)     58 (47.9)             
  PD-1 expression                                                                          0.805
    Low                                                43 (44.8)     40 (43.0)             
    High                                               53 (55.2)     53 (57.0)             
  TIL expression                                                                   0.193   0.002
    TIL^−^                                             60 (49.6)     37 (30.3)             
    TIL^+^                                             61 (50.4)     85 (69.7)             
  PD-L1 expression                                                                 0.144   0.023
    PD-L1^−^                                           89 (73.6)     73 (59.8)             
    PD-L1^+^                                           32 (26.4)     49 (40.2)             

According to the 7th edition of the American Joint Committee on Cancer staging system.

NLR data was missing for 2 patients. C, contingency coefficient; MMR, mismatch repair; pMMR, MMR-proficient; dMMR, MMR-deficient; NLR, neutrophil-lymphocyte ratio; CRP, C-reactive protein; PD-1, programmed death-1; TIL, tumor-infiltrating lymphocyte; PD-L1, programmed death ligand-1.

###### 

Aberrant protein expression in MMR-deficient patients.

  Aberrant protein expression   Cases, n (%)
  ----------------------------- --------------
  MMR ([@b1-ol-0-0-9826])       44 (36.1)
    MLH1                          9 (7.4)
    MSH2                          4 (3.3)
    MSH6                        25 (20.5)
    PMS2                          6 (4.9)
  MMR ([@b2-ol-0-0-9826])       68 (55.7)
  MMR ([@b3-ol-0-0-9826])         7 (5.7)
  MMR ([@b4-ol-0-0-9826])         3 (2.5)

MMR ([@b1-ol-0-0-9826]), negative expression of 1 MMR protein; MMR ([@b2-ol-0-0-9826]), concurrent negative expression of 2 MMR proteins; MMR ([@b3-ol-0-0-9826]), concurrent negative expression of 3 MMR proteins; MMR ([@b4-ol-0-0-9826]), concurrent negative expression of 4 MMR proteins. MMR, mismatch repair; MLH1, MutL homolog 1; MSH2, MutS homolog 2; MSH6, MutS homolog 6; PMS2, PMS1 homolog 2.

###### 

Association analysis between TILs and PD-L1 expression in colorectal cancer cells.

         TIL^+^, n (%)   TIL^−^, n (%)                                   
  ------ --------------- --------------- ----------- ----------- ------- -------
  pMMR   11 (18.0)       50 (82.0)       21 (35.0)   39 (65.0)   0.189   0.034
  dMMR   36 (42.4)       49 (57.6)       13 (35.1)   24 (64.9)           0.455
  All    47 (32.2)       99 (67.8)       34 (35.1)   63 (64.9)           0.643

MMR, mismatch repair; pMMR, MMR-proficient; dMMR, MMR-deficient; C, contingency coefficient; TIL, tumor-infiltrating lymphocyte; PD-L1, programmed death ligand-1.

###### 

Association analysis of TIL/PD-L1 status with clinicopathological features using a χ^2^ test.

  Characteristic                                       TIL^+^ PD-L1^+\ [b](#tfn6-ol-0-0-9826){ref-type="table-fn"}^   TIL^+^ PD-L1^−\ [b](#tfn6-ol-0-0-9826){ref-type="table-fn"}^   TIL^−^ PD-L1^+\ [b](#tfn6-ol-0-0-9826){ref-type="table-fn"}^   TIL^−^ PD-L1^−\ [b](#tfn6-ol-0-0-9826){ref-type="table-fn"}^   C       P-value
  ---------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ------- ---------
  Age at diagnosis, years                                                                                                                                                                                                                                                                                                  0.751
    \<60                                               28 (59.6)                                                      51 (51.5)                                                      20 (58.8)                                                      33 (52.4)                                                              
    ≥60                                                19 (40.4)                                                      48 (48.5)                                                      14 (41.2)                                                      30 (47.6)                                                              
  Sex                                                                                                                                                                                                                                                                                                                      0.271
    Male                                               23 (48.9)                                                      63 (63.6)                                                      22 (64.7)                                                      34 (54.0)                                                              
    Female                                             24 (51.1)                                                      36 (36.4)                                                      12 (35.3)                                                      29 (46.0)                                                              
  Primary tumor site                                                                                                                                                                                                                                                                                                       0.297
    Left colon                                         11 (23.4)                                                      37 (37.4)                                                      14 (41.2)                                                      28 (44.4)                                                              
    Right colon                                        26 (55.3)                                                      37 (37.4)                                                      13 (38.2)                                                      23 (36.5)                                                              
    Rectum                                             10 (21.3)                                                      25 (25.3)                                                        7 (20.6)                                                     12 (19.0)                                                              
  Stage^[a](#tfn5-ol-0-0-9826){ref-type="table-fn"}^                                                                                                                                                                                                                                                               0.389   \<0.001
    I                                                  13 (27.7)                                                      33 (33.3)                                                        1 (2.9)                                                        1 (1.6)                                                              
    II                                                 29 (61.7)                                                      47 (47.5)                                                      20 (58.8)                                                      39 (61.9)                                                              
    III                                                  4 (8.5)                                                      17 (17.2)                                                        8 (23.5)                                                     17 (27.0)                                                              
    IV                                                   1 (2.1)                                                        2 (2.0)                                                        5 (14.7)                                                       6 (9.5)                                                              
  Tumor stage                                                                                                                                                                                                                                                                                                      0.396   \<0.001
    T1                                                   2 (4.3)                                                        9 (9.1)                                                        0 (0.0)                                                        0 (0.0)                                                              
    T2                                                 12 (25.6)                                                      30 (30.3)                                                        1 (2.9)                                                        2 (3.2)                                                              
    T3                                                 27 (57.4)                                                      51 (51.5)                                                      24 (70.6)                                                      43 (68.3)                                                              
    T4a                                                  5 (10.6)                                                       8 (8.1)                                                        6 (17.6)                                                     12 (19.0)                                                              
    T4b                                                  1 (2.1)                                                        1 (1.0)                                                        3 (8.8)                                                        6 (9.5)                                                              
  Node stage                                                                                                                                                                                                                                                                                                       0.227   0.004
    Negative                                           43 (91.5)                                                      82 (82.8)                                                      23 (67.6)                                                      42 (66.7)                                                              
    Positive                                             4 (8.5)                                                      17 (17.2)                                                      11 (32.4)                                                      21 (33.3)                                                              
  Tumor histological grade                                                                                                                                                                                                                                                                                         0.279   0.015
    Well-differentiated                                  0 (0.0)                                                        2 (2.0)                                                        0 (0.0)                                                        0 (0.0)                                                              
    Moderately differentiated                          30 (63.8)                                                      65 (65.7)                                                      14 (41.2)                                                      33 (52.4)                                                              
    Poorly differentiated                                5 (10.6)                                                     18 (18.2)                                                        8 (23.5)                                                       6 (9.5)                                                              
    Mucinous                                           12 (25.5)                                                      14 (14.1)                                                      12 (35.3)                                                      24 (38.1)                                                              
  Vascular invasion                                                                                                                                                                                                                                                                                                        0.166
    No                                                 46 (97.9)                                                      92 (92.9)                                                      29 (85.3)                                                      56 (88.9)                                                              
    Yes                                                  1 (2.1)                                                        7 (7.1)                                                        5 (14.7)                                                       7 (11.1)                                                             
  Nerve invasion                                                                                                                                                                                                                                                                                                   0.256   0.001
    No                                                 45 (95.7)                                                      94 (94.9)                                                      28 (82.4)                                                      48 (76.2)                                                              
    Yes                                                  2 (4.3)                                                        5 (5.1)                                                        6 (17.6)                                                     15 (23.8)                                                              
  NLR                                                                                                                                                                                                                                                                                                              0.235   0.003
    Low (≤5)                                           41 (87.2)                                                      98 (99.0)                                                      27 (81.8)                                                      53 (85.5)                                                              
    High (\>5)                                           6 (12.8)                                                       1 (1.0)                                                      6 (18.2%)                                                        9 (14.5)                                                             
  CRP, mg/l                                                                                                                                                                                                                                                                                                        0.311   \<0.001
    Low (≤5)                                           23 (50.0)                                                      80 (80.8)                                                      15 (48.4)                                                      30 (47.6)                                                              
    High (\>5)                                         23 (50.0)                                                      19 (19.2)                                                      16 (51.6)                                                      33 (52.4)                                                              
  PD-1 expression                                                                                                                                                                                                                                                                                                  0.315   \<0.001
    Low                                                  7 (18.9)                                                     33 (43.4)                                                        9 (36.0)                                                     34 (66.7)                                                              
    High                                               30 (81.1)                                                      43 (56.6)                                                      16 (64.0)                                                      17 (33.3)                                                              
  MMR status                                                                                                                                                                                                                                                                                                       0.268   \<0.001
    pMMR                                               11 (23.4)                                                      50 (50.5)                                                      21 (61.8)                                                      39 (61.9)                                                              
    dMMR                                               36 (76.6)                                                      49 (49.5)                                                      13 (38.2)                                                      24 (38.1)                                                              

According to the 7th edition of the American Joint Committee on Cancer staging system.

n (%). C, contingency coefficient; MMR, mismatch repair; pMMR, MMR-proficient; dMMR, MMR-deficient; NLR, neutrophil-lymphocyte ratio; CRP, C-reactive protein; PD-1, programmed death-1; TIL, tumor-infiltrating lymphocyte; PD-L1, programmed death ligand-1.

###### 

Multivariate multinomial logistic regression analysis of risk factors for TIL^+^ PD-L1^+^ status.

                                                         TIL^−^ PD-L1^−^            TIL^−^ PD-L1^+^   TIL^+^ PD-L1-                                                     
  ------------------------------------------------------ -------------------------- ----------------- ------------------------- ------------ -------------------------- ------------
  Stage (reference, stage IV)                                                       All \>0.05                                  All \>0.05   All P\>0.05                All \>0.05
  Tumor stage (reference, T4b)                                                      All \>0.05                                  All \>0.05   All P\>0.05                All \>0.05
  Negative lymph node metastasis (reference, positive)     1.889 (0.030--120.105)   0.764               1.072 (0.014--83.342)   0.975        21.414 (0.093--4946.861)   0.764
  Tumor histological grade (reference, mucinous)                                    All \>0.05                                  All \>0.05                              All \>0.05
  No nerve invasion (reference, nerve invasion)            6.533 (0.935--45.646)    0.058               1.058 (0.100--11.239)   0.963        0.417 (0.036--4.826)       0.484
  Low NLR level (reference, high NLR level)                0.677 (0.100--4.569)     0.689               0.588 (0.082--4.214)    0.598        N/A                        
  Low CRP level (reference, high CRP level)                0.735 (0.209--2.585)     0.631               1.409 (0.343--5.786)    0.634        2.697 (0.871--8.351)       0.085
  Low PD-1 expression (reference, high expression)       10.473 (3.005--36.503)     \<0.001             2.017 (0.490--8.295)    0.331        3.443 (1.145--10.352)      0.028
  pMMR (reference, dMMR)                                 11.536 (3.223--41.290)     \<0.001           14.523 (3.358--62.803)    \<0.001      4.718 (1.607--13.848)      0.005

TIL^+^ PD-L1^+^ status was taken as reference. OR, odds ratio; CI, confidence interval; TIL, tumor-infiltrating lymphocyte; PD-L1, programmed death ligand-1; NLR, neutrophil-lymphocyte ratio; CRP, C-reactive protein; PD-1, programmed death-1; pMMR, mismatch repair-proficient; dMMR, MMR-deficient.
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